Advancing mRNA Vaccines and Therapeutics from Discovery to Commercialization with Enhanced Extrahepatic Delivery, Extended Dosing Durability, and Optimized Safety Profiles Across Oncology, Rare Diseases, and Infectious Pathogens.
The 5th mRNA-Based Therapeutics Summit returns to Boston, uniting 320+ experts from Moderna, Pfizer, BioNTech & more to explore breakthroughs in cancer vaccines, cell therapy & gene editing. Join 4 content tracks spanning discovery to manufacturing, and gain insights to accelerate your 2025 pipeline from lab to clinic.
Deepen mechanistic insight into VEGF×PD-1, sharpen target selectivity, and optimize binding affinity to accelerate bispecific discovery in oncology and autoimmune indications.
Unpack the latest in VEGF×PD-1 biology, target pairing, and binding optimization to drive next-gen bispecifics. With ivonescimab showing a 49% PFS gain in NSCLC, momentum is building. As bispecifics expand into autoimmune and TCEs, the 16th World Bispecific Summit offers real-world insights to overcome translational hurdles and accelerate smarter, safer therapeutic design.
Advance your ADC strategy—connect with top pharma, biotech, and investors to refine differentiation, validate platforms, and secure partnerships in a focused, efficient networking environment.
Join the 2nd ADC & Novel Conjugates Partnering & Investment Summit to connect with global drug developers, biotech leaders, and investors driving the future of targeted therapeutics. Explore strategic partnerships, platform validation, and differentiation across ADCs, radioconjugates, and immunotoxins. Through curated networking and expert insight, accelerate investment and innovation in next-gen conjugates.
Celebrate a decade of CAR-TCR innovation and gain actionable insights to overcome today’s toughest cell therapy hurdles—from solid tumor targeting to scalable, cost-effective manufacturing.
With clinical momentum accelerating across autoimmune and oncology cell therapies, the 10th CAR-TCR Summit unites the field to reflect on a decade of progress and tackle today’s biggest challenges. From solid tumor targeting to scalable manufacturing and biomarker development, join experts across discovery to late-stage development to gain practical solutions and shape the future of cell therapy.